{"organizations": [], "uuid": "180840d9abb32ec0ea0e5b4d3a7fc4140b1782f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-horizon-pharma-q1-non-gaap-earning/brief-horizon-pharma-q1-non-gaap-earnings-per-share-0-03-idUSASC0A0WX", "country": "US", "domain_rank": 408, "title": "BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T19:16:00.000+03:00", "replies_count": 0, "uuid": "180840d9abb32ec0ea0e5b4d3a7fc4140b1782f9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-horizon-pharma-q1-non-gaap-earning/brief-horizon-pharma-q1-non-gaap-earnings-per-share-0-03-idUSASC0A0WX", "ord_in_thread": 0, "title": "BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "horizon pharma plc", "sentiment": "negative"}, {"name": "brief-horizon pharma", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Horizon Pharma PLC:\n* REPORTS STRONG FIRST-QUARTER 2018 ORPHAN AND RHEUMATOLOGY NET SALES GROWTH; INCREASES FULL-YEAR 2018 GUIDANCE AND ANNOUNCES NEW COMPANY OPERATING STRUCTURE TO ENHANCE FOCUS ON RARE DISEASES\n* SEES FY 2018 SALES $1.17 BILLION TO $1.2 BILLION * Q1 NON-GAAP EARNINGS PER SHARE $0.03\n* Q1 GAAP LOSS PER SHARE $0.96 * Q1 SALES $223.9 MILLION VERSUS I/B/E/S VIEW $233.1 MILLION\n* Q1 EARNINGS PER SHARE VIEW $0.06 â€” THOMSON REUTERS I/B/E/S\n* SEES 2018 ADJUSTED EBITDA GUIDANCE RANGE TO $390 MILLION TO $415 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T19:16:00.000+03:00", "crawled": "2018-05-10T17:43:45.066+03:00", "highlightTitle": ""}